

Dear ILTE Investigator,

the 2008 follow up is now in progress and the some centers already returned their forms. Please remember the deadline of APRIL 3rd, 2009.

Inside these form you certainly noted that we will collect data on BM cytogenetics performed in pts on imatinib since >5 years. This information will be very useful in my opinion to generate knowledge on the usefulness of the BM aspirate procedure after 5 years of treatment and could be quickly published. I know that several centers use to stop BMA even earlier but there is no data on which to base such a decision.

I expect these data to be publishable quite quickly since they will offer hard data on which to base clinical decisions.

For this reason the ILTE Steering Committee discussed this issue and adopted the general rule of ILTE for authorship (number of evaluable patients enrolled) but adapted to the particular series of patients analyzed, i.e. those with BM cytogenetics available after 5 years.

Therefore we will count for this particular sub-study only the actual number of patients with these characteristics whose data will be entered in the F-U form.

We also plan to have an internal meeting at EHA where the updated results will be discussed.

With best regards.

Carlo Gambacorti-Passerini MD  
ILTE study Chairman